Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
1.
Clin Exp Dermatol ; 39(3): 385-90, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24772485

RESUMO

The differences in systemic T-cell responses between patients with psoriatic arthritis (PsA) and patients with cutaneous psoriasis (Ps) are still largely unknown. To determine differential features that could be used to distinguish PsA from Ps, we compared the cytokine secretion profile of circulating T cells in patients with PsA, patients with cutaneous Ps and control subjects. We determined Th1, Th2 and Th17 cytokine secretion of anti-CD3-stimulated peripheral blood mononuclear cells (PBMCs) using a cytokine bead array. Normality of data distribution was assessed by the Shapiro-Wilk test, and statistical significance was calculated by the Mann-Whitney test. Phenotypic characterization of circulating T cells was performed by fluorescence-activated cell sorting analysis. We found that the major systemic differences distinguishing PsA from cutaneous Ps were the increased secretion of interleukin (IL)-2 by α-CD3-stimulated PBMCs and a higher percentage of circulating CD3+ T cells expressing the proliferation marker CD71 in PsA. These results indicate IL-2 as a possible biomarker of PsA, and suggest a role of circulating T cells with high proliferative capacity in the pathogenesis of PsA.


Assuntos
Artrite Psoriásica/metabolismo , Complexo CD3/imunologia , Interleucina-2/metabolismo , Leucócitos Mononucleares/metabolismo , Psoríase/metabolismo , Adolescente , Adulto , Citocinas/metabolismo , Feminino , Citometria de Fluxo , Humanos , Leucócitos Mononucleares/imunologia , Masculino , Pessoa de Meia-Idade , Linfócitos T Auxiliares-Indutores/metabolismo , Adulto Jovem
2.
G Ital Dermatol Venereol ; 148(5): 501-4, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24005143

RESUMO

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease with heterogeneous clinical presentation and unpredictable course but often with a tendency to irreversible joint damage. Joint damage can occur early in the disease also in the absence of significant clinical signs of arthritis. These observations and the current availability of effective treatments in controlling skin and joint disease underline the importance of early diagnosis of PsA. The use of specific questionnaires for screening patients at risk of psoriatic arthritis, knowledge of new classification criteria for PsA and especially the proper use of new imaging techniques are all important steps in achieving the goal of early diagnosis of PsA. The dermatologist may play a key role in this regard supported, when necessary, by the collaboration of the rheumatologist and radiologist.


Assuntos
Artrite Psoriásica/diagnóstico , Artrite Psoriásica/classificação , Artrite Psoriásica/diagnóstico por imagem , Diagnóstico por Imagem , Diagnóstico Precoce , Humanos , Imageamento por Ressonância Magnética , Valor Preditivo dos Testes , Radiografia , Sensibilidade e Especificidade , Inquéritos e Questionários , Avaliação de Sintomas , Ultrassonografia
3.
Int J Immunopathol Pharmacol ; 25(3): 617-26, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23058012

RESUMO

We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2⁻) in response to phorbol myristate acetate (PMA) or to N-formyl-methionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O2⁻ overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CD11b membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor Gö6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), Gö6976 (an inhibitor of α and α PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 µM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.


Assuntos
Quimiotaxia de Leucócito/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Proteína Quinase C/antagonistas & inibidores , Inibidores de Proteínas Quinases/farmacologia , Pirróis/farmacologia , Quinazolinas/farmacologia , Superóxidos/metabolismo , Antígeno CD11b/metabolismo , Células Cultivadas , Relação Dose-Resposta a Droga , Fator Estimulador de Colônias de Granulócitos e Macrófagos/metabolismo , Humanos , Interleucina-1beta/metabolismo , Interleucina-8/metabolismo , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/enzimologia , Proteína Quinase C/metabolismo , Receptores de Formil Peptídeo/metabolismo , Acetato de Tetradecanoilforbol/farmacologia , Fatores de Tempo , Fator de Necrose Tumoral alfa/metabolismo
4.
Neurol Sci ; 31(3): 337-9, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19924503

RESUMO

Previous reports have suggested an increased risk of psoriasis in MS patients. Worsening of dermatologic lesions during interferon therapy has been rarely reported, but activation of psoriatic arthritis has not been described until now. The following is a case report. A 37-year-old woman affected by relapsing-remitting multiple sclerosis had severe worsening of cutaneous psoriasis and activation of psoriatic arthritis during interferon beta treatment. The symptoms resolved after therapy discontinuation. This case further supports that activation of psoriasis might be a rare side effect of IFNB therapy and suggests careful evaluation of concomitant morbidity to allow a patient-oriented treatment strategy.


Assuntos
Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/uso terapêutico , Interferon beta/efeitos adversos , Interferon beta/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Psoríase/induzido quimicamente , Adulto , Artrite Psoriásica/induzido quimicamente , Artrite Psoriásica/complicações , Artrite Psoriásica/patologia , Feminino , Humanos , Esclerose Múltipla Recidivante-Remitente/complicações , Esclerose Múltipla Recidivante-Remitente/patologia , Psoríase/complicações , Psoríase/patologia , Índice de Gravidade de Doença
5.
Int J Immunopathol Pharmacol ; 22(1): 243-6, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19309573

RESUMO

Amicrobial pustulosis associated with autoimmune diseases (APAD) is a clinical entity which was described only recently and few cases are reported in the literature. This condition is characterized by recurrent acute onset with pustular lesions predominantly involving skin folds, genitals, scalp and external auditory canals of young women. The etiopathogenesis of APAD is unknown and the most effective therapeutic treatment seems to be systemic corticosteroids. We describe the case of a 16-year old female patient suffering from APAD successfully treated with cyclosporine A.


Assuntos
Doenças Autoimunes/tratamento farmacológico , Ciclosporina/uso terapêutico , Imunossupressores/uso terapêutico , Dermatopatias Vesiculobolhosas/tratamento farmacológico , Adolescente , Feminino , Humanos
6.
Ann Rheum Dis ; 68(3): 397-9, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18812393

RESUMO

OBJECTIVES: To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments. METHODS: Recruitment criteria were age 18-65 years, no history of thrombosis, positivity for lupus anticoagulant and/or IgG/IgM anticardiolipin antibody (aCL) on > or =2 occasions at least 6 weeks apart. Demographic, laboratory and clinical parameters were collected at enrolment and at the time of the thrombotic event. RESULTS: 370 patients/subjects (mean (SD) age 34 (9.9) years) were analysed retrospectively for a mean (SD) follow-up of 59.3 (45.5) months. Thirty patients (8.1%) developed a first thrombotic event during follow-up. Hypertension and medium/high levels of IgG aCL were identified by multivariate logistic regression analysis as independent risk factors for thrombosis. Thromboprophylaxis during high-risk and long-term periods was significantly protective. CONCLUSIONS: Hypertension or medium/high titres of IgG aCL are risk factors for a first thrombotic event in asymptomatic aPL carriers and primary prophylaxis is protective.


Assuntos
Anticorpos Antifosfolipídeos/sangue , Síndrome Antifosfolipídica/imunologia , Heterozigoto , Trombose/etiologia , Adolescente , Adulto , Idoso , Anticorpos Anticardiolipina/sangue , Síndrome Antifosfolipídica/genética , Métodos Epidemiológicos , Feminino , Humanos , Hipertensão/complicações , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Trombose/imunologia , Trombose/prevenção & controle , Adulto Jovem
7.
Int J Immunopathol Pharmacol ; 21(2): 437-45, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18547491

RESUMO

We evaluated the effect of efalizumab on neutrophil and monocyte functions. The in vitro pre-incubation with efalizumab concentrations similar to those reached during in vivo therapy almost completely saturated CD11a binding sites without affecting the membrane expression of CD11b, CD128a or CD128b. There was a significant reduction in the chemotactic activity of the pre-treated cells toward three different chemo-attractants, whereas their phagocytic capacity and production of oxygen radicals remained unchanged. One month after the administration of efalizumab to five patients with psoriasis (T1) circulating neutrophil counts increased by 34% from pre-therapy (T0) with no change in the number of monocytes. In the same patients the CD11a binding sites on phagocytes were >90% saturated, and there was also a significant down-modulation on neutrophils (44% of T0) and monocytes (63% of T0). In line with in vitro results, efalizumab treatment caused a significant deficiency in the chemotactic properties of neutrophils and monocytes, but no changes in phagocytosis, oxidative burst, production of pro-inflammatory cytokines or the membrane expression of CD11b, CD128a and CD128b. Our findings suggest that neutrophils and monocytes may be among the targets of efalizumab activity in patients with psoriasis.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/imunologia , Psoríase/tratamento farmacológico , Psoríase/imunologia , Acridinas/farmacologia , Adulto , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Humanizados , Antígenos CD11/biossíntese , Quimiotaxia/efeitos dos fármacos , Feminino , Citometria de Fluxo , Humanos , Masculino , Pessoa de Meia-Idade , Monócitos/metabolismo , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/metabolismo , Fagócitos/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Fenótipo , Espécies Reativas de Oxigênio/metabolismo , Receptores de Interleucina-8A/biossíntese , Receptores de Interleucina-8B/biossíntese , Explosão Respiratória/efeitos dos fármacos , Acetato de Tetradecanoilforbol/farmacologia
8.
Reumatismo ; 60(1): 6-13, 2008.
Artigo em Italiano | MEDLINE | ID: mdl-18432320

RESUMO

Osteonecrosis of the jaw (ONJ) is a well-known devastating side effect of parenteral bisphosphonate therapy for cancer. Several ONJ cases have been reported in patients taking oral bisphosphonates for osteoporosis or Paget's disease. Even if the number of cases of ONJ in patients taking oral bisphosphonates are still rare compared to the total exposure, rheumatologists treating bone diseases with bisphosphonates must be aware of this new complication, allowing for prevention and early diagnosis. The patients must be informed on the benefit/risk of bisphosphonate therapy and, when necessary and possible, alternative therapy for postmenopausal osteoporosis should be considered. The need for the patient to be dentally fit and to maintain this state forever should be part of the informed consent for bisphosphonate treatment. It is uncommon for rheumatologists to ask about dental problems but this new bisphosphonate- associated complication highlights the need for this to change. In this paper we review the literature available on this newly described bisphosphonate-induced complication with particular emphasis on ONJ cases related to the use of oral bisphosphonates.


Assuntos
Conservadores da Densidade Óssea/efeitos adversos , Difosfonatos/efeitos adversos , Doenças Maxilomandibulares/induzido quimicamente , Osteonecrose/induzido quimicamente , Humanos , Doenças Maxilomandibulares/epidemiologia , Doenças Maxilomandibulares/terapia , Osteonecrose/epidemiologia , Osteonecrose/terapia , Fatores de Risco
11.
Clin Exp Rheumatol ; 22(3): 331-4, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15144128

RESUMO

OBJECTIVE: Since the early activation antigen CD69 has been implicated in the pathogenesis of some inflammatory diseases, we evaluated the expression of the molecule on peripheral blood (PB) and synovial fluid (SF) neutrophils obtained from RA patients and its possible correlation with PB and SF cytokine concentration. METHODS: CD69 membrane expression (and CD11b as control marker) was assessed by indirect immunofluorescence and flow cytometry analysis on purified PB and SF neutrophils. Cytokine levels (GM-CSF, IFN-gamma, TNF-alpha) in plasma and SF supernatants were measured by ELISA. RESULTS: CD69 was absent on control neutrophils, while it was expressed on PB neutrophils from RA patients although no detectable GM-CSF, IFN-gamma or TNF-alpha was observed in their plasma. CD69 expression was still more evident on SF neutrophils from RA patients; 59% had detectable levels of INF-gamma in their SF while GM-CSF and TNF-alpha were detectable in SF from 95% and 33% of RA patients, respectively. However, no correlation was observed between cytokine concentrations and CD69 expression on SF neutrophils. SF but not PB neutrophils from RA patients expressed increased amounts of CD11b when compared to control PB neutrophils without any correlation with CD69 membrane expression. CONCLUSION: The activation antigen CD69 is significantly expressed on PB and SF neutrophils from RA patients. However, the mechanism(s) of induction and its possible role in the pathogenesis of RA remain to be defined.


Assuntos
Antígenos CD/metabolismo , Antígenos de Diferenciação de Linfócitos T/metabolismo , Artrite Reumatoide/sangue , Neutrófilos/metabolismo , Líquido Sinovial/citologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Citocinas/sangue , Humanos , Lectinas Tipo C , Ativação Linfocitária , Pessoa de Meia-Idade , Líquido Sinovial/metabolismo
12.
Clin Exp Rheumatol ; 21(6): 759-62, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14740456

RESUMO

We report a patient with longstanding systemic lupus erythematosus (SLE) who developed pure red cell aplasia (PRCA). This condition is rare in connective tissue diseases and is reported in 32 previous cases of SLE in literature. Our patient recovered, apparently in response to treatment with high dosage of corticosteroids, but relapse occurred when the prednisone dosage was tapered down to 10 mg/day. The patient was successfully treated with cyclosporin A with no recurrence of the disease in the last 2 years.


Assuntos
Ciclosporina/administração & dosagem , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Aplasia Pura de Série Vermelha/complicações , Aplasia Pura de Série Vermelha/tratamento farmacológico , Adulto , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Humanos , Infusões Intravenosas , Lúpus Eritematoso Sistêmico/diagnóstico , Aplasia Pura de Série Vermelha/diagnóstico , Medição de Risco , Índice de Gravidade de Doença , Resultado do Tratamento
13.
J Interferon Cytokine Res ; 19(7): 705-10, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10454340

RESUMO

In chronic granulomatous disease, interferon-gamma (IFN-gamma) significantly reduces the incidence and severity of recurrent infections, but its effectiveness administered ex novo during acute infection has been reported in only one case. In this report, we describe two adult brothers with chronic granulomatous disease treated successfully with IFN-gamma for acute liver abscesses. Two brothers with severe recurrent infections of unknown origin were hospitalized for septic fever, malnutrition, and ultrasonographic evidence of liver abscess. Autosomal recessive chronic granulomatous disease was diagnosed based on lack of superoxide anion production by phagocytes and absence of p47-phox protein. An antibiotic regimen specifically directed against Staphylococcus aureus was ineffective, whereas treatment with 50 microg/m2 IFN-gamma s.c. thrice weekly induced complete healing with scarring within 3 months. No septic recurrence was observed during a 4-year follow-up period. In chronic granulomatous disease, IFN-gamma is effective not only in preventing but also in healing life-threatening acute infections.


Assuntos
Doença Granulomatosa Crônica/tratamento farmacológico , Interferon gama/uso terapêutico , Abscesso Hepático/tratamento farmacológico , Adolescente , Adulto , Genes Recessivos , Doença Granulomatosa Crônica/genética , Humanos , Abscesso Hepático/complicações , Medições Luminescentes , Masculino
14.
Eur J Dermatol ; 9(5): 390-2, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10417445

RESUMO

Proximal white subungual onychomycosis (PWSO) is a rare form of nail infection that occurs almost exclusively in immunocompromised patients. Initially, in several reports, PWSO was described in ARC and AIDS patients. Later this pattern of onychomycosis was observed in patients with renal transplants, who received immunosuppressive therapy, and recently in a woman with active systemic lupus erythematosus (SLE) treated with systemic steroid therapy. We report a case of recurrent PWSO in a woman affected by a defect of polymorphonuclear chemotaxis. The association between PWSO and a defect of neutrophil chemotaxis, not yet described in the literature, suggests a point of discussion about the role of polymorphonuclear leucocyte functions in the defense mechanisms of the host affected by dermatophytosis. In this report the close association between PWSO and an immunocompromised condition is once again described. For this reason the authors emphasize the importance of investigating the common and uncommon causes of immunodeficiency in all patients affected by PWSO.


Assuntos
Quimiotaxia de Leucócito , Onicomicose/imunologia , Adolescente , Feminino , Humanos , Neutrófilos/imunologia , Onicomicose/patologia , Recidiva
15.
Cell Immunol ; 189(1): 51-9, 1998 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-9758694

RESUMO

Monocytes differentiating in vitro into macrophages increase their capacity to ingest particles via FcgammaR and CR3. Because human recombinant IL-10 is a potent up-regulator of phagocytosis in human monocytes, we investigated whether spontaneously produced IL-10 could be a signal for the modulation of phagocytosis by cultured monocytes. We show here that culture of monocytes in the presence of anti-IL-10 mAb completely abolished up-regulation of phagocytosis of both EIgG and EIgMC3bi, suggesting a role for spontaneously produced IL-10 in the modulation of phagocytosis by cultured human monocytes. The inhibition exerted by anti-IL-10 mAb on the development of FcgammaR-mediated ingestion was dependent on the concomitant inhibition of FcgammaRIII induction in cultured cells. On the other hand, a similar down-regulation of CR3 expression was not involved in the inhibitory effect exerted by anti-IL-10 mAb on the development of CR3-mediated ingestion. Monocytes secreted detectable levels of IL-10 when cultured in medium but the concentrations of IL-10 in the supernatants decreased with length of time in culture, the decrease being completely reversed by anti-IL-10 mAb. In addition, we showed that monocytes expressed immunoreactive IL-10 on their surface and this expression increased during differentiation into macrophages. Whether this IL-10 was bound to specific membrane receptors or it was an integral membrane protein remains to be determined; however, this latter possibility is consistent with our observations that IL-10 did not elute with acid treatment and exogenous IL-10 did not increase surface staining of monocytes. Our data indicate that human mononuclear phagocytes express IL-10 on their membrane and suggest that this cytokine may represent an autocrine signal for the increased phagocytic function observed during differentiation of monocytes into macrophages.


Assuntos
Interleucina-10/biossíntese , Monócitos/imunologia , Fagócitos/fisiologia , Anticorpos Monoclonais/imunologia , Membrana Celular/metabolismo , Células Cultivadas , Humanos , Monócitos/metabolismo , Receptores de Complemento/biossíntese , Receptores de IgG/biossíntese
16.
Scand J Immunol ; 45(3): 269-75, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9122616

RESUMO

The authors investigated the ability of interleukin-10 (IL-10) to modulate some constitutive or interferon-gamma (IFN-gamma)-enhanced activities of human neutrophils. An 18h culture of neutrophils with IL-10 dose-dependently down-regulated their capacity to produce O(2)- and lucigenin-amplified chemiluminescence in response to n-formyl-methionyl-leucylphenyl-alanine (FMLP). Furthermore, treatment of neutrophils with IL-10 decreased in a dose-dependent fashion, their capacity to lyse antibody-coated sheep erythrocytes. Membrane expression of Fc gamma RI, Fc gamma RII, Fc gamma RIII, CR1, CR3 and Fc gamma R- and CR-mediated phagocytosis were not modified by the cytokine. Culture of neutrophils with IFN-gamma (100 U/ml) did not modify their Fc gamma R- and CR-mediated phagocytosis, but significantly up-regulated Fc gamma RI and CR3 membrane expression as well as their oxidative metabolism and antibody-dependent cellular cytotoxicity (ADCC). When IL-10 and IFN-gamma were added simultaneously to neutrophil culture, IL-10 dose-dependently reduced IFN-gamma-induced increase of CR3 expression, O(2)- production (in response to both FMLP and phorbol 12-myristate 13-acetate, or PMA) and ADCC, but did not change Fc gamma RI expression on phagocytes. These results demonstrate that IL-10 is a significant neutrophil deactivator and provide new information on the role of IL-10 in the regulation of neutrophil-mediated inflammatory processes.


Assuntos
Citotoxicidade Celular Dependente de Anticorpos , Regulação para Baixo/imunologia , Interleucina-10/farmacologia , Neutrófilos/imunologia , Explosão Respiratória/imunologia , Citotoxicidade Celular Dependente de Anticorpos/efeitos dos fármacos , Células Cultivadas , Regulação para Baixo/efeitos dos fármacos , Humanos , Neutrófilos/efeitos dos fármacos , Oxirredução/efeitos dos fármacos , Receptores de Complemento/efeitos dos fármacos , Receptores de IgG/efeitos dos fármacos , Explosão Respiratória/efeitos dos fármacos
17.
Peptides ; 17(4): 675-9, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8804079

RESUMO

The proopiomelanocortin-derived peptide alpha-melanocyte stimulating hormone (alpha-MSH) has potent anti-inflammatory effects in all animal models of inflammation against which it has been tested. Understanding of the mechanism by which this occurs is incomplete, although there is recent evidence for alpha-MSH receptors in murine and human macrophages and for modulation of production of proinflammatory cytokines and related mediators by alpha-MSH. Because of the prominence of neutrophils in early stages of inflammatory reactions where alpha-MSH is effective, we examined human neutrophils for evidence of mRNA for alpha-MSH receptors and for inhibition of neutrophil chemotaxis. There was accumulation of mRNA for melanocortin receptor 1 (MC1) in RT/PCR product from neutrophils stimulated with interferon and LPS. In subsequent studies alpha-MSH inhibited migration of neutrophils from most normal volunteers when the cells were placed in FMLP or IL-8 gradients. The inhibition by alpha-MSH could be traced to alterations in cAMP in neutrophils. The presence of alpha-MSH receptor message in neutrophils is consistent with the established anti-inflammatory effects of the peptide. Direct inhibition of neutrophil chemotaxis likely contributes to the anti-inflammatory activity of alpha-MSH.


Assuntos
Quimiotaxia de Leucócito/efeitos dos fármacos , Neutrófilos/fisiologia , Receptores do Hormônio Hipofisário/fisiologia , alfa-MSH/sangue , alfa-MSH/farmacologia , Análise de Variância , AMP Cíclico/sangue , Primers do DNA , Humanos , Interleucina-8/farmacologia , Lipopolissacarídeos/farmacologia , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/efeitos dos fármacos , Nitritos/sangue , Reação em Cadeia da Polimerase , RNA Mensageiro/biossíntese , RNA Mensageiro/sangue , Receptores da Corticotropina/biossíntese , Receptores de Melanocortina , Receptores do Hormônio Hipofisário/biossíntese , Proteínas Recombinantes/farmacologia , Acetato de Tetradecanoilforbol/farmacologia , Transcrição Gênica/efeitos dos fármacos
18.
Dermatology ; 193(2): 88-93, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8884141

RESUMO

BACKGROUND: An unclassified amicrobial pustular dermatosis particularly affecting the main cutaneous folds, external auditory canals and scalp and coexisting with systemic lupus erythematosus has been recently described. OBJECTIVE: We studied 3 young females bearing such cutaneous manifestations in association with subacute cutaneous lupus erythematosus, celiac disease and various serum autoantibodies, respectively, in order to further characterize this possibly new entity. METHODS: Various routine and immunological laboratory tests, histopathologic and direct immunofluorescence examinations and in vitro studies of neutrophil function were performed in each patient. RESULTS: We reported our findings and compared our cases with the few others appearing in the literature. We documented an impaired neutrophil chemotaxis in 2 subjects, but neutrophil dysfunction does not seem to be one of the verifying criteria. CONCLUSIONS: All of these cases may represent a distinctive form in the clinicopathological spectrum of neutrophilic dermatoses (ND) because of the typical distribution and the close link with different autoimmune disorders. Cimetidine in combination with ascorbic acid can be indicated as an effective and safe alternative to the classic medications of ND, although the action of both drugs remains unexplained.


Assuntos
Doenças Autoimunes/complicações , Lúpus Eritematoso Cutâneo/complicações , Dermatopatias Vesiculobolhosas/complicações , Adulto , Ácido Ascórbico/uso terapêutico , Autoanticorpos/sangue , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Doença Celíaca/complicações , Quimiotaxia de Leucócito , Cimetidina/uso terapêutico , Meato Acústico Externo/patologia , Feminino , Técnica Direta de Fluorescência para Anticorpo , Antagonistas dos Receptores H2 da Histamina/uso terapêutico , Humanos , Lúpus Eritematoso Cutâneo/tratamento farmacológico , Lúpus Eritematoso Cutâneo/imunologia , Lúpus Eritematoso Cutâneo/patologia , Neutrófilos/imunologia , Neutrófilos/fisiologia , Dermatoses do Couro Cabeludo/complicações , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatoses do Couro Cabeludo/imunologia , Dermatoses do Couro Cabeludo/patologia , Pele/patologia , Dermatopatias Vesiculobolhosas/tratamento farmacológico , Dermatopatias Vesiculobolhosas/imunologia , Dermatopatias Vesiculobolhosas/patologia
19.
J Leukoc Biol ; 58(3): 351-8, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-7665991

RESUMO

Interleukin-10 (IL-10), a cytokine produced by type 2 helper T (Th2) cells, inhibits the microbicidal effector function of interferon-gamma (IFN-gamma)-activated macrophages. However, recent observations indicate that IL-10, like IFN-gamma, increases Fc gamma RI expression and Fc gamma R-mediated cytotoxic activity on human monocytes, suggesting that this cytokine cannot be classified purely as a monocyte deactivator. The present study found that incubation for 40 h of human monocytes or monocyte-derived macrophages in the presence of IL-10 caused a significant enhancement of their capacity to ingest particles coated with immunoglobulin G (Fc gamma R-mediated ingestion) or with C3b/C3bi fragments of the complement system (CR1/CR3-mediated ingestion). The number of phagocytosing cells (% phagocytosis) and the number of ingested particles per cell (phagocytic index) were both significantly higher after 40-h incubation of monocytes with IL-10 concentrations > or = 1 U/ml. This up-regulating activity on phagocytosis was completely reversed by anti-IL-10 monoclonal antibody (mAb). As previously reported, IL-10 stimulated Fc gamma RI expression on monocytes but did not induce the expression of Fc gamma RII, Fc gamma RIII, CR1, and CR3. IFN-gamma, like IL-10, up-regulated only Fc gamma RI expression but significantly reduced both Fc gamma R- and CR-mediated ingestion. IL-10 almost completely reversed the IFN-gamma-induced inhibition of both Fc gamma R- and CR-mediated phagocytosis, without concomitant changes in membrane expression of phagocytic receptors. Exposure of monocytes to IL-4 reduced the membrane expression of all three Fc gamma Rs and also inhibited Fc gamma R-mediated ingestion. On the other hand, IL-4 up-regulated both CR3 expression and CR-mediated ingestion on cultured monocytes. IL-10 not only neutralized the down-regulatory effect of IL-4 on Fc gamma R expression but also completely reversed the IL-4-induced suppression of Fc gamma R-mediated phagocytosis. Exposure of monocytes to a combination of IL-10 and IL-4 resulted in a synergistic effect on CR-mediated ingestion, even though no additive effects were observed on CR membrane expression. Finally, culture of monocytes in medium containing anti-IL-10 mAb significantly reduced their capacity to ingest IgG- or C3b/C3bi-coated particles, suggesting a role for endogenously produced IL-10 in the modulation of phagocytosis by human monocytes.(ABSTRACT TRUNCATED AT 400 WORDS)


Assuntos
Interferon gama/administração & dosagem , Interleucina-10/administração & dosagem , Interleucina-4/administração & dosagem , Monócitos/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Humanos , Técnicas In Vitro , Receptores de Complemento/fisiologia , Receptores de IgG/fisiologia , Regulação para Cima/efeitos dos fármacos
20.
Haematologica ; 80(2): 123-9, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7628750

RESUMO

BACKGROUND: 31D8 monoclonal antibody (mAb) has been shown to bind heterogeneously to human neutrophils, identifying subsets of cells which differ in their functional response to chemotactic stimuli. In this study we used 31D8 mAb to determine whether differences in neutrophil subpopulations might explain the long-lasting decreased chemotaxis observed in bone marrow transplant recipients. METHODS: Thirty patients with self-sustaining hematopoiesis 1 to 5 years bone marrow transplantation (BMT) (15 allogeneic and 15 autologous) performed for acute lymphocytic leukemia (ALL, 10 patients) or acute myelogenous leukemia in complete remission (8 patients), Hodgkin's lymphoma (2 patients), chronic myeloid leukemia (8 patients) and severe aplastic anemia (2 patients) were included in the study. Neutrophil chemotaxis was evaluated using a modified Boyden chamber assay and 31D8 binding was determined by indirect immunofluorescence and cytofluorimetric analysis. RESULTS: Neutrophil chemotaxis was significantly impaired in the BMT group with respect to controls. The chemotactic defect strikingly correlated with autologous BMT and, in particular, with ALL as the pre-existing disease. No differences between patients and controls were observed in the percentage of 31D8 bright and dull neutrophils. However, when mean fluorescence intensity (MFI) was analyzed as a relative measure of 31D8 antigen expression on the overall neutrophil population, a significant decrease was observed in neutrophils from BMT patients with respect to controls. As for chemotaxis, the impairment of 31D8 binding was more evident in autologous BMT and strikingly correlated with ALL as the pre-existing disease regardless of age, sex and time since BMT. Moreover, a significant positive correlation between impaired chemotaxis and decreased 31D8 binding was found in our patients. CONCLUSIONS: These findings suggest that the decreased neutrophil chemotaxis observed in some BMT patients may be due in part to circulating 31D8 dull neutrophils, although the causes for the decreased 31D8 binding and for the quite pronounced neutrophil defect in ALL patients remain unknown.


Assuntos
Anticorpos Monoclonais/imunologia , Antígenos de Diferenciação/imunologia , Transplante de Medula Óssea/efeitos adversos , Quimiotaxia de Leucócito , Síndromes de Imunodeficiência/etiologia , Neutrófilos/imunologia , Adolescente , Adulto , Anemia Aplástica/imunologia , Anemia Aplástica/terapia , Transplante de Medula Óssea/imunologia , Quimiotaxia de Leucócito/efeitos dos fármacos , Feminino , Seguimentos , Doença de Hodgkin/imunologia , Doença de Hodgkin/terapia , Humanos , Leucemia/imunologia , Leucemia/terapia , Masculino , Pessoa de Meia-Idade , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/patologia , Zimosan/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...